Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
30)/b27-17+
Molecular Weight: 471
Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation
and inhibited both anchorage-dependent and -independent proliferation in the pancreatic cancer cell line PANC-1
InChi: InChI=1S/C23H22N8O/c1-14-15(11-24)6-4-8-17(14)18-10-19(28-22(25)27-18)20-13-31(30-29-20)12-16-7-5-9-21(26-16)23(2
MK-3697 p-016 30)/b27-17+MK 3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK 3697 is also the third insomnia drug, currently being developed by Merck. MK 3697 has Ki = 0. 95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK 3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. Product information CAS Number:
US$ 13.00
US$ 14.95
US$ 130.00
US$ 39.00
US$ 155.00